Brent L. Saunders is CEO & Chairman +1 at Allergan plc (AGN). They have made 14 open-market trades across 6 companies since 2007, most recently 2026-05-22.
CIK 0001268854
12 open-market purchases totalling $5.6M since 2015, against 2 sales. Across 12 scored buys the stock is down 3.6% at ninety days, and 8.6 points behind the S&P over the same stretch.
12 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 67% | 50% |
| Avg Move | +0.4% | -2.5% | -3.6% |
| Alpha | -0.1% | -3.9% | -8.6% |
| Scored | 12 | 12 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BLCO | BUY | 2026-03-06 | 2026-03-10 | $17.14 | $252K | -9.0% | -4.6% | -12.1% |
| BLCO | BUY | 2025-05-22 | 2025-05-27 | $11.28 | $248K | -0.9% | +2.2% | +23.0% |
| SPRY | SELL | 2025-05-20 | 2025-05-22 | $14.25 | $1.7M | -4.8% | +14.1% | +0.6% |
| SKIN | BUY | 2024-08-12 | 2024-08-13 | $1.08 | $44K | +33.1% | +12.3% | +35.4% |
| BLCO | BUY | 2024-08-05 | 2024-08-07 | $15.66 | $505K | +1.1% | +0.3% | +24.8% |
| SKIN | BUY | 2023-08-16 | 2023-08-17 | $6.10 | $362K | +4.6% | +1.7% | -68.6% |
| BBIO | BUY | 2021-12-29 | 2022-01-03 | $14.48 | $255K | -24.9% | -40.7% | -30.5% |
| AGN | BUY | 2019-03-07 | 2019-03-07 | $143.68 | $376K | +8.5% | +6.0% | -10.9% |
| AGN | BUY | 2018-03-08 | 2018-03-08 | $152.53 | $503K | +5.6% | +4.5% | +0.3% |
| AGN | BUY | 2017-12-06 | 2017-12-06 | $164.74 | $758K | +2.9% | +3.8% | -9.2% |
| AGN | BUY | 2017-03-29 | 2017-09-18 | $242.67 | $21K | -8.1% | -15.7% | -23.0% |
| AGN | BUY | 2016-11-21 | 2016-11-21 | $189.13 | $2.0M | -2.2% | +0.0% | +27.4% |
| AGN | BUY | 2015-08-21 | 2015-08-24 | $301.94 | $302K | -6.3% | +0.3% | +0.3% |
| SGP | SELL | 2007-04-27 | 2007-05-01 | $31.64 | $1.1M | +18.8% | +10.0% | +10.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| SPRY |
| 120,000 |
| $481K |
| FRX | 255,299 | — |
| Total | $135.4M |
Shares reported on the most recent Form 4, priced at the 2026-05-26 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.